Results 291 to 300 of about 51,741 (305)

Immunogenicity of three-dose COVID-19 vaccines in people living with multiple sclerosis. [PDF]

BMJ Neurol Open
Shawe-Taylor MJ, Greenwood D, He A, Hobbs A, Dowgier G, Penn R, Sanderson T, Stevenson-Leggett P, Bazire J, Harvey R, Champsas D, Sharmin S, Aojula A, Bianchi A, Al-Araji S, Hacohen Y, Yam C, Mohamud S, Christensen R, Moccia M, Crick COVID Serology Pipeline, Legacy Investigators, Libri V, Kassiotis G, Gamblin S, Lewis N, Williams B, Swanton C, Gandhi S, Bauer D, Wu M, Carr E, Wall E, Ciccarelli O.   +33 more
europepmc   +1 more source

Estimating the decay of protective antibodies induced by SARS-CoV-2 mRNA vaccination and hybrid immunity. [PDF]

Npj Viruses
Roe MD, Coggins SA, Darcey ES, Goguet E, Haines-Hull H, Esposito D, Olsen CH, Pollett SD, Mitre E, Laing ED.   +9 more
europepmc   +1 more source

Quantitative Immunoglobulin G and Interferon-Gamma Responses After Different Booster Strategies of CoronaVac and BNT162b2 Vaccines in Türkiye. [PDF]

Infect Dis Clin Microbiol
Ocaklı Aİ, Özyar-Kurtçu ŞA, Uzun M, Kaşıkçı-Çavdar M, Telli-Dizman G, Metan G, Akova M, Sarıbaş Z, Şener B.   +8 more
europepmc   +1 more source

Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: A randomized non-inferiority trial. [PDF]

Sci Rep
Salako A, Musa A, Ige F, Abdullahi A, James A, Ekama S, Odubela O, Idigbe I, Ajibaye O, Altaf M, Adeneye K, Akinsolu FT, Olojo I, Okwuraiwe A, Egharevba H, Ekpenyong M, Elemuwa U, Ezenyi I, Bitrus F, Odubela O, Oba A, Idris G, Yusuf J, Akande I, Nwaiwu S, Omale L, Oyewunmi O, Agbabiaka A, Eyinade O, Ogunwale J, Garba A, Bello Y, Musa B, Ezejiofor O, Ejiro B, Iwalokun B, Rosenzweig L, Adigwe O, Adeyeye C, Shuaib F, Wicek W, Hamada Y, Ezechi O, Gupta R, Salako B.   +44 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Decreased Infectivity Following BNT162b2 Vaccination

SSRN Electronic Journal, 2021
Background: BNT162b2 was shown to be 92% effective in preventing COVID-19. Prioritizing vaccine rollout, and achievement of herd immunity depend on SARS-CoV-2 transmission reduction. The vaccine’s effect on infectivity is thus a critical priority. Methods: In a cohort of all 9650 HCW of a large single tertiary medical center, we calculated the ...
Gili Regev-Yochay, Sharon Amit, Moriah Bergwerk, Marc Lipsitch, Eyal Leshem, Rebecca Kahn, Yaniv Lustig, Carmit Cohen, Ram Doolman, Arnona Ziv, Ilya Novikov, Carmit Rubin, Irena Gimpelevich, Amit Huppert, Galia Rahav, Arnon Afek, Yitshak Kreiss   +16 more
openaire   +1 more source

Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19

JAMA Internal Medicine
This case-control study estimates the association between receipt of the BNT162b2 XBB vaccine and medically attended COVID-19 outcomes among US adults 18 years and older.
S. Tartof, J. Slezak, Timothy B Frankland, L. Puzniak, V. Hong, B. Ackerson, Julie A. Stern, J. Zamparo, Sarah Simmons, L. Jodar, J. M. McLaughlin   +10 more
semanticscholar   +1 more source